Martin Fan
Stock Analyst at Wedbush
(4.77)
# 127
Out of 5,042 analysts
11
Total ratings
72.73%
Success rate
52.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Fan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARTV Artiva Biotherapeutics | Maintains: Outperform | $18 → $23 | $5.41 | +325.14% | 2 | Oct 17, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Outperform | $35 → $40 | $23.90 | +67.40% | 2 | Oct 9, 2025 | |
| ANAB AnaptysBio | Reiterates: Outperform | $45 | $35.07 | +28.31% | 3 | Sep 30, 2025 | |
| SANA Sana Biotechnology | Initiates: Outperform | $5 | $5.59 | -10.55% | 1 | Sep 24, 2025 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $38 | $9.16 | +314.85% | 1 | Jul 9, 2025 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $8 | $2.15 | +272.09% | 1 | May 28, 2025 | |
| ORKA Oruka Therapeutics | Reiterates: Outperform | $40 | $27.22 | +46.95% | 1 | May 15, 2025 |
Artiva Biotherapeutics
Oct 17, 2025
Maintains: Outperform
Price Target: $18 → $23
Current: $5.41
Upside: +325.14%
Zenas BioPharma
Oct 9, 2025
Maintains: Outperform
Price Target: $35 → $40
Current: $23.90
Upside: +67.40%
AnaptysBio
Sep 30, 2025
Reiterates: Outperform
Price Target: $45
Current: $35.07
Upside: +28.31%
Sana Biotechnology
Sep 24, 2025
Initiates: Outperform
Price Target: $5
Current: $5.59
Upside: -10.55%
Cartesian Therapeutics
Jul 9, 2025
Initiates: Outperform
Price Target: $38
Current: $9.16
Upside: +314.85%
Aclaris Therapeutics
May 28, 2025
Initiates: Outperform
Price Target: $8
Current: $2.15
Upside: +272.09%
Oruka Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $40
Current: $27.22
Upside: +46.95%